Frederic Dhermain
Overview
Explore the profile of Frederic Dhermain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
1763
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baumert B, Jaspers J, Keil V, Galldiks N, Izycka-Swieszewska E, Timmermann B, et al.
Radiother Oncol
. 2024 Oct;
202:110594.
PMID: 39454886
Purpose: This guideline will discuss radiotherapeutic management of IDH-mutant grade 2 and grade 3 diffuse glioma, using the latest 2021 WHO (5th) classification of brain tumours focusing on: imaging modalities,...
2.
Kacimi S, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, et al.
J Clin Oncol
. 2024 Oct;
43(3):329-338.
PMID: 39356975
Purpose: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV)...
3.
Aboubakr O, Moiraghi A, Elia A, Tauziede-Espariat A, Roux A, Leclerc A, et al.
J Neurosurg
. 2024 Aug;
142(1):174-186.
PMID: 39213667
Objective: Glioblastoma, isocitrate dehydrogenase (IDH)-wildtype is the most aggressive glioma with poor outcomes. The authors explored survival rates and factors associated with long-term survival in patients harboring a glioblastoma, IDH-wildtype....
4.
Roth P, Gorlia T, Reijneveld J, de Vos F, Idbaih A, Frenel J, et al.
Neuro Oncol
. 2024 Mar;
26(9):1670-1682.
PMID: 38502052
Background: Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of...
5.
6.
Botticella A, Dhermain F
Curr Opin Neurol
. 2023 Oct;
36(6):587-591.
PMID: 37865858
Purpose Of Review: The incidence of brain metastasis is high and still increasing. Among local therapies, stereotactic radiosurgery (SRS) is an effective treatment option, optimally sparing normal brain, even for...
7.
Aboubakr O, Metais A, Hasty L, Saffroy R, Zanello M, Pallud J, et al.
J Neuropathol Exp Neurol
. 2023 Oct;
82(11):958-962.
PMID: 37812786
No abstract available.
8.
Bozzao A, Weber D, Crompton S, Braz G, Csaba D, Dhermain F, et al.
J Cancer Policy
. 2023 Aug;
38:100438.
PMID: 37634617
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCCs) are explanations of the organisation and actions necessary to provide high-quality care to patients with a specific cancer type. They...
9.
Berard C, Truillet C, Larrat B, Dhermain F, Esteve M, Correard F, et al.
Pharmacol Ther
. 2023 Aug;
250:108518.
PMID: 37619931
The therapeutic management of gliomas remains particularly challenging. Brain tumors present multiple obstacles that make therapeutic innovation complex, mainly due to the presence of blood-tumor and blood-brain barriers (BTB and...
10.
Martz N, Salleron J, Dhermain F, Vogin G, Daisne J, Mouttet-Audouard R, et al.
Radiat Oncol
. 2023 Jul;
18(1):113.
PMID: 37408055
Purpose: Radiotherapy is, with surgery, one of the main therapeutic treatment strategies for meningiomas. No prospective study has defined a consensus for the delineation of target volumes for meningioma radiotherapy....